Which dolutegravir patents “ran out,” and where is the loss of patent coverage happening?
Dolutegravir is a drug (sold by brands such as Tivicay) covered by patents that differ by country and by the specific rights being enforced (for example, the original compound/patent terms and later patents on formulations or use). Patent protection can also end at different times for different manufacturers and different jurisdictions, so “dolutegravir patent loss” typically means that some patents have expired or are no longer enforceable in a given market, allowing generic versions to launch there.
To answer precisely, you need two details:
1) the country (or market) you mean, and
2) the specific brand/product line (e.g., which label/formulation) and whether you mean compound patents, secondary patents, or both.
When did dolutegravir patent protection end (key dates people search)?
Exact dates depend on the jurisdiction and on the particular patent(s) involved. Without the country and patent number, any specific “expiration date” would be guesswork. In general, people look up expiry dates based on:
- the priority/filing date of the underlying patent family,
- any extensions (where allowed),
- and any linkages to regulatory exclusivity or litigation outcomes that can delay generic entry.
If you share the country (for example, US, UK, India, South Africa, Kenya, etc.), I can narrow down the relevant expiry timeline.
Can generic dolutegravir enter immediately when a patent expires?
Often, but not always. Even after patent expiry, market entry can still be delayed by:
- other still-in-force patents (including formulation or dosing patents),
- regulatory data exclusivity or marketing exclusivity rules,
- and patent disputes or injunctions that can temporarily block launch.
So “patent lost” can be a step toward generic availability, but entry timing can still vary.
What do you mean by “lost of patent” in practice—expiration or court cancellation?
People use “loss of patent” to mean different things:
- expiration by time, or
- a court decision invalidating or narrowing claims, or
- settlement terms that allow some generics while others may still be blocked.
If you tell me whether you mean “expired” or “invalidated/canceled,” I can tailor the explanation.
How to check dolutegravir patent status yourself (fastest way)
Patent status is best confirmed through:
- national patent registers for the relevant country, and
- drug/patent linkage systems where they exist (these list which patents are tied to specific products and what’s still in force).
If you tell me the country and (if available) the brand name you’re tracking, I can outline exactly what to look for.
Quick clarification so I can give the exact answer
Which country are you asking about, and is this about dolutegravir itself (Tivicay) or a specific fixed-dose combination (like dolutegravir + abacavir/lamivudine, etc.)?